$IRTC

Smith Mervin sold $75K of IRTC

Smith Mervin (EVP Strategic Business Ops) sold 617 shares of iRhythm Holdings, Inc. (IRTC) at $122.12 on 2026-08-03.

Original reporting
SEC EDGAR · Smith Mervin
Published Aug 4, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
high confidence
Mentioned
$IRTC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The only new fact is the insider sale details (shares, price, total value, post-transaction holdings). There is no accompanying company-specific catalyst such as guidance, contract, or regulatory action.

02

Market read

Traders may note insider selling, but the disclosed transaction is small and lacks fundamental implications.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it does not provide intent, tax context, or whether other insiders are selling/buying around the same period.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-04, transaction dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc.

Company-level read

Ticker impact

$IRTCNeutralHigh confidence
Context

iRhythm Holdings Form 4 shows EVP Strategic Business Ops Smith Mervin sold 617 shares on 2026-08-03 for about $75.3K.

Expected impact

Low near-term impact; any price reaction would be more sentiment-driven than fundamentals-driven.

Evidence & confidence

The filing is a Form 4 insider transaction, not an earnings, guidance, deal, or regulatory event. The transaction value (~$75K) is modest relative to typical company market caps, and the article provides no new operational or financial information.

Market effects

No clear sector read-through from a single small insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the signal may be overstated.

Key entities

  • iRhythm Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Smith Mervin

    EVP Strategic Business Ops who sold 617 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

$IRTCMedAI 9/10

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.